Evidence map›Paper›PMID 41175629›Full record

ReviewJournal of diabetes and its complications2026

Soluble Tumor Necrosis Factor Receptors (sTNFRs) as biomarkers for Diabetic Kidney Disease.

Emily Moroney, Monika A Niewczas, Elif I Ekinci, Richard J MacIsaac

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of diabetes and its complications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily MoroneyDepartment of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
Monika A NiewczasResearch Division, Joslin Diabetes Center, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Elif I EkinciAustralian Centre for Accelerating Diabetes Innovations, Melbourne Medical School, University of Melbourne, Parkville, VIC 3052, Australia; Department of Endocrinology, Austin Health, Melbourne, Australia; Department of Medicine, Melbourne Medical School, Parkville, VIC 3052, Australia.
Richard J MacIsaacDepartment of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; Department of Medicine, Melbourne Medical School, Parkville, VIC 3052, Australia; Department of Medicine St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Victoria, Australia. Electronic address: r.macisaac@unimelb.edu.au.

Funding

Understanding the role of the Complement Proteome in progressive Diabetic Kidney DiseaseR01DK123459 · NIDDK · JOSLIN DIABETES CENTER · PI NIEWCZAS, MONIKA ANNA · 2020 to 2024
$2.3M
Proteomic Biomarkers Prognostic for Diabetic Wound HealingR61DK131915 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI NIEWCZAS, MONIKA ANNA, VEVES, ARISTIDIS · 2022 to 2023
$1.1M
NIDDK NIH HHS R01 DK123459NIDDK NIH HHS R61 DK131915
6 · The paper itself

Abstract

Multiple biomarkers have been associated with Diabetic Kidney Disease (DKD) progression and its associated exaggerated risk for cardiovascular events and mortality. Chronic inflammation plays an important role in the progression of DKD. Tumor Necrosis Factor alpha (TNF-α) is a central proinflammatory cytokine that binds to its soluble receptor (sTNFR) and has been implicated in the pathogenesis of DKD. sTNFRs are a family of membrane proteins that regulate gene expression and activate cell death pathways. They are involved in the immune system and can bind to cytokines related to TNF. Higher levels of the type 1 (sTNFR1) and type 2 (sTNFR2) receptor have consistently been associated with progressive DKD, notably rapid GFR decline and progression to kidney failure. They offer enhanced risk prediction for progressive DKD over and above established risk markers. Higher levels of sTNFR1 and sTNFR2 also predict incident cardiovascular disease and mortality in people with diabetes. Further studies are required to define the temporal relationship between changes in circulating sTNFR levels and progression of kidney function loss. The influence of medications with kidney protective effects on sTNFR levels also requires further investigation.

Indexed as

Diabetic NephropathiesReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIBiomarkersDisease ProgressionHumansBiomarkersReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIBiomarkersDiabetes mellitusDiabetic complicationsDiabetic kidney diseaseDiabetic nephropathysTNFR

Identifiers

PMID41175629
PMCPMC13091037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.